MODERN SLAVERY STATEMENT

2021-2022
REPORTING ENTITY

DOCUMENT PREPARED FOR

Peter MacCallum Cancer Institute
(Trading as Peter MacCallum Cancer Centre)
ABN: 42 100 504 883

Peter MacCallum Cancer Foundation Ltd
ABN: 14 786 237 480

Cell Therapies Pty Ltd
(Centre for Blood Cell Therapies)
ACN: 100 285 916
ABN: 15 100 285 916

Address:
305 Grattan Street
Melbourne VIC 3002

This 2021-22 Modern Slavery Statement has been prepared by the Peter MacCallum Cancer Centre (Peter Mac) and outlines the steps we have taken as an organisation to identify, manage and mitigate specific risks around modern slavery in our operations and supply chains.

The statement captures the activities of Peter Mac and the entities controlled by it. It has been prepared by our Procurement team in collaboration with our Executive and with our controlled entities Cell Therapies Pty Ltd and Peter MacCallum Cancer Foundation Ltd.

This Modern Slavery Statement was approved by the Board of Directors of Peter MacCallum Cancer Institute, as defined by the Modern Slavery Act 2018 (Cth) (the Act) on 7 March 2023.

This Modern Slavery Statement is signed by a responsible Member of Peter MacCallum Cancer Institute, as defined by the Act.²

Prof. Maxine Morand AM
Board Chair

Prof. Shelley Dolan
Chief Executive

---

1 Section 4 of the Act defines a principal governing body as: (a) the body, or group of members of the entity, with primary responsibility for the governance of the entity; or (b) if the entity is of a kind prescribed by rules made for the purposes of this paragraph—a prescribed body within the entity, or a prescribed member or members of the entity.

2 Section 4 of the Act defines a responsible member as: (a) an individual member of the entity’s principal governing body who is authorised to sign modern slavery statements for the purposes of this Act; or (b) if the entity is a trust administered by a sole trustee—that trustee; or (c) if the entity is a corporation sole—the individual constituting the corporation; or (d) if the entity is under administration within the meaning of the Corporations Act 2001—the administrator; or (e) if the entity is of a kind prescribed by rules made for the purposes of this paragraph—a prescribed member of the entity.
1. CONTENTS

1. About Peter Mac
   Vision 02
   Values 02

2. Our Supply Chains
   Melbourne Health 07
   HealthShare Victoria 07
   PPP arrangement – Victorian Comprehensive Cancer Centre 07
   Pharmacy – Merlin 08
   Food and beverage - CBORD 08

3. Peter Mac Modern Slavery Risks
   Peter Mac's identified modern slavery risks 09
   HSV risk assessment of Peter Mac contracts 2021-22 10
   The Peter MacCallum Cancer Foundation 11
   Cell Therapies Pty Ltd 11

4. The Past Year – A review of Our Modern Slavery Action Plan
   Educating our staff 13
   Identify our risks 13
   Working with our suppliers and HSV 14
   Working with HSV 14
   Formalising our framework 14

5. The Year Ahead 2022–2023
   Educating our staff 16
   Identify our risks 16
   Working with our suppliers 16
   Formalise our framework 16

Appendix 1. References 18
Appendix 2. Peter Mac Supplier Risk Categorisation 19
Appendix 3. Contract Spend Over $1m 20
Appendix 4. Supplier Annual Spend Over $1m 22
1. ABOUT PETER MAC

Peter MacCallum Cancer Centre (Peter Mac) is a world leading cancer research, education and treatment centre and Australia’s only health service solely dedicated to caring for people affected by cancer.

We have over 3,300 staff, including more than 750 laboratory and clinical researchers across five sites, including:

- Bendigo
- Box Hill
- Melbourne
- Moorabbin
- Sunshine

Operations span across five different areas - laboratory, clinical, translational, health services and implementation research - all focused on providing better treatments, better care and potential cures for cancer.

Peter Mac has played a leading role in understanding the causes of cancer and improving how the disease is prevented, diagnosed, managed and treated, for the benefit of Victorians and Australians for over 70 years.

“We are a cancer centre unsurpassed in the world, where humanity, caring service and relentless research share equal value. Nothing but the best is good enough in the treatment of cancer.”

— Sir Peter MacCallum, Co-founder

Vision

To provide the best in cancer care, accelerating discovery and translating to cures. Peter Mac is a proud, mission-driven organisation that leads on a global scale.

Values

- **Excellence** - ensuring that clinical practice is evidence-based and patient-centred and is provided by qualified and experienced staff who are accountable and appropriately credentialed.

- **Innovation** - fostered by supporting research and a learning culture.

- **Compassion** - adhering to the strongest ethical standards to ensure a culture of openness, mutual respect and trust is at our core.
SNAPSHOT 2021-2022

Inpatient separations by cancer tumour stream

**44,741 IN TOTAL**

- Haematology
- Breast
- Melanoma & Skin
- Lower Gastrointestinal
- Genitourinary
- Head & Neck
- Lung
- Upper Gastrointestinal
- Gynaecology

- Sarcoma
- General Physician
- Paediatrics/Late Effects
- Neurology

**40,832 Patients**

**44,741 Inpatient separations**

**32,204 Telehealth appointments**

**28% increase in telehealth appointments**

**285,080 Specialist appointments**

**32,900 outpatient Allied Health occasions of service**

**32,884 inpatient Allied Health occasions of service**

Cellular Immunotherapy (CAR-T)

**27 total patients** were treated (infused) with the approved standard of care CAR-T over the 2021-22 year. All 27 patients were treated for aggressive lymphoma with Kymriah (Novartis) or Yescarta (Kite/Gilead)

**9 different CAR-T clinical trials** were open throughout this period

**3,930 Employees (2,675 FTE)**

**Financial performance**

**181 Volunteers**

**$819m Revenue**

**$138m Research**

**$294,000 Statement of Priorities surplus**
Surgery

3,307
Elective surgery patients

Radiology scans

<table>
<thead>
<tr>
<th>Patients</th>
<th>Courses of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiotherapy</td>
<td>5,932</td>
</tr>
<tr>
<td>Gamma knife</td>
<td>229</td>
</tr>
</tbody>
</table>

14,100 CT scans
5,902 Ultrasound scans
5,888 MRI scans
5,649 X-Ray scans

Research

40 Research laboratories
630 Active clinical trials

700 Researchers
1,229 Publications, including 210 in high-impact journals

3,327 Nuclear Medicine Scans
1,788 Radionuclide Therapy patient consultations

9,584 PET Scans
792 Radionuclide Therapy treatments

Pathology requests

189,550

519 Average pathology requests per day
34,058 Molecular pathology tests

Pharmacy

74,518 Prescriptions items dispensed (outpatients)
51,065 Doses of chemotherapy and immunotherapy for day patients

31,235 Medicines supplied (inpatients)
2. OUR SUPPLY CHAINS

In May 2022 Peter Mac’s supply chain underwent a transformation resulting in the implementation of Peter Mac’s own Financial Management Information System (FMIS) and the cessation of the relationship with Melbourne Health for purchasing, and supply chain support and activities.

Since this change did not occur until May 2022, the information contained within this report will reflect the first 10 months under the original operating model, and two months under the current ongoing model.

Peter Mac’s supply chain is derived through the following streams:

**Pre May 2022**
- Peter Mac direct to supplier purchases – offline purchases
- Melbourne Health Supply Chain – includes HSV contracts and precinct contracts
- Pharmacy purchases via MERLIN (HSV contract)
- Food and beverage purchases via CBORD

**Post May 2022**
- Peter Mac direct to supplier purchases – offline purchases
- Peter Mac direct to supplier purchases - from May 2022 via Peter Mac’s own FMIS system
- Direct to HSV- from May 2022 via Peter Mac’s own FMIS system (HSV contracts)
- Pharmacy Purchases via MERLIN (HSV Contract)
- Food and beverage purchases via CBORD

The breakdown of expenses across these are provided in **Figure 1**.

---

**Figure 1. 2021-22 Expense Summary by Supply Chain**

<table>
<thead>
<tr>
<th>Supply Chain</th>
<th>Percentage</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Mac Merlin</td>
<td>33%</td>
<td>$101.9m</td>
</tr>
<tr>
<td>Peter Mac Direct Invoices Offline</td>
<td>38%</td>
<td>$117.4m</td>
</tr>
<tr>
<td>Peter Mac CBORD</td>
<td>28%</td>
<td>$1.4m</td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td>$86.7m</td>
</tr>
</tbody>
</table>

- Melbourne Health to May 2022: $86.4m (22%)  
- Peter Mac Purchasing May - June 2022: $18.4m (6%)
Melbourne Health

In May 2022 the purchasing and supply chain functions were transferred back to Peter Mac. Peter Mac’s purchasing activity via Melbourne Health Supply Chain until May 2022, accounted for $68.4m, approximately 22% of Peter Mac’s overall operational spend during this period.

HealthShare Victoria

HealthShare Victoria (HSV) is a state-wide supply chain organisation that partners with Victorian public health services to procure best-value goods and services. HSV works in partnership with public health services to understand their requirements, facilitate large-scale collective tenders and manage common-use contracts on behalf of the state. Peter Mac purchases the goods and services it needs from the suppliers who are party to HSV collective agreements. As such, it is recognised that HSV has a significant role in health service supply chains.

HSV works with approximately 449 Tier 1 suppliers and is responsible for more than 65 contracts with a spend value of over $1.16 billion.

HSV contracts cover a broad range of services, equipment and supplies across a number of categories including ventilators, beds, mattresses, patient trolleys, treatment chairs, hypodermic needles and syringes, gloves, pharmaceutical products, IV fluids, agency labour, catering supplies, laundry and linen services and non-emergency patient transport. A full list of HSV’s sourcing categories can be found at https://www.HSV.org.au/contracts-and-documents/contracts.

Early 2022, HSV took over the operations of the Melbourne Health distribution centre, relocated it to a larger premise in based in Derrimut Victoria and rebranded it under HSV. HSV commenced distribution of nominated contracted products directly to participating health services. Whilst HSV’s distribution centre commenced deliveries March 2022, Peter Mac continued to receive deliveries via Melbourne Health until May 2022, when Peter Mac’s FMIS was fully implemented. This allowed for Peter Mac to commence receiving deliveries direct from HSV’s distribution centre and removed Peter Mac’s reliance on Melbourne Health.

The spend represented in Figure 1 above of approximately $86m includes the deliveries from Melbourne Health until May 2022 as well as the direct deliveries from HSV post May 2022.

PPP arrangement – Victorian Comprehensive Cancer Centre

The Victorian Comprehensive Cancer Centre (VCCC - Peter Mac’s Parkville campus), operates under a Public-Private Partnership (PPP). This agreement is between the State Government of Victoria and Plenary Health. The VCCC Project Agreement is the contract binding all parties for the 25-year life of the agreement.

The VCCC Project Agreement clearly defines the roles and responsibilities of the:

- State (Department of Health)
- Facility Owner (Plenary Health)
- Facility Manager (Honeywell FM)
- Facility Operator (Peter MacCallum Cancer Centre)

Whilst the VCCC Project Agreement binds all parties, the contract is held between the State Government and Plenary Health. Plenary Health in turn have a contract with Honeywell as the facility management company. Consequently, Peter Mac does not have any contractual relationship with Plenary or Honeywell. Unfortunately, this means Peter Mac has limited visibility of the terms within the contracts Honeywell and Plenary hold with suppliers, as well as the selection process or selection criteria, in particular how they manage modern slavery. Both organisations do submit a Modern Slavery Statement annually to the Australian Border Force, which Peter Mac has access to.
Honeywell’s Business Code of Conduct outlines Honeywell’s commitment to respect for human rights. Honeywell also expects its supply chain to abide by its Supplier Code of Business Conduct. Their code of conduct details Honeywell’s requirements and the expectations they place on their suppliers in relation to compliance with modern slavery policies and principles. As the Facility Manager, Honeywell have subcontracted a number of services including electrical contractors, plumbers, security, waste collection, pest control, medical gas supply, cleaning, carpark management to name a few.

Plenary introduced and adopted a modern slavery policy declaring zero tolerance for all forms of modern slavery. This policy applies to all employees across its entities. Since last year’s report, Plenary have advanced their modern slavery capabilities and have requested their Tier 1 suppliers to complete a modern slavery questionnaire which allows them to assess and determine the risk rating associated with that supplier and to determine appropriate action to mitigate any risk of modern slavery breaches moving forward.

Peter Mac’s Facilities team are responsible for managing the VCCC Project Agreement contract on behalf of the state. Servicing of the PPP Contract accounted for a spend of $7.7m during the 2021-22 financial year, approximately 1% of Peter Mac’s overall expenditure. This figure is included in Figure 1 above in the section titled “Peter Mac Direct Invoices Offline”.

Pharmacy – Merlin

The pharmaceutical team manage all purchases via a separate FMIS system called Merlin. These purchases are based on HSV contracts and account for $101m or 33% of Peter Mac’s spend. Deliveries are direct from the supplier to Peter Mac. The contracts are managed by HSV on behalf of the health services. Currently Peer Mac Procurement have little to no involvement with pharmaceutical contracts or the subsequent modern slavery risks associated with the supply chain. This is managed by HSV.

Food and beverage - CBORD

The Peter Mac food and beverage team manage all requirements via a specialised FMIS system called CBORD. The entire food and beverage spend utilise and leverage HSV contracts, with deliveries direct from the supplier to Peter Mac. Peter Mac Procurement currently have limited or no involvement in their operations, contracts or requirements. The modern slavery risk is managed by HSV.
3. PETER MAC MODERN SLAVERY RISKS

Peter Mac’s identified modern slavery risks

The risks of modern slavery for Peter Mac arise through its supply chains.

In 2021-22 the Procurement team was continuing to manage the challenges of COVID-19 and the impact to its supply chain. In the initial year of COVID the focus was on supply shortages of PPE, medical supplies and alternative supply markets. As COVID has continued the market is having to juggle not only raw material shortages and freight concerns but also suppliers exiting challenging markets.

Initially the Procurement team’s focus was on products that fell under the Healthcare category below, such as PPE and medical devices. In 2022-23 the Procurement team will continue to work in the Healthcare space but will also look to expand its scope to include suppliers within the food services category.

Specific areas of concern and the associated risks are identified in Figure 2 below.

Figure 2. Supply Chain Risks

<table>
<thead>
<tr>
<th>INDUSTRY SECTORS</th>
<th>POTENTIAL RISKS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Construction, Property Management &amp; Services</td>
<td>• Complex subcontractor arrangements can mask poor recruitment and employment practices. In particular the exploitation of migrant workers</td>
</tr>
<tr>
<td>• Facilities</td>
<td>• Historically low priority in procurement frameworks</td>
</tr>
<tr>
<td>• Cleaning</td>
<td>• Use of child and forced labour in production of bricks, cement, granite, rubber and timber</td>
</tr>
<tr>
<td>• Utilities</td>
<td>• Potential exposure to risk of debt bondage of adult and child workers, passport confiscations and limitation of movement.</td>
</tr>
<tr>
<td>• Waste management</td>
<td>• Underpayment of staff in fruit picking and production</td>
</tr>
<tr>
<td>• Security</td>
<td>• Passport confiscation, use of &quot;deposits&quot; to work in Australia</td>
</tr>
<tr>
<td>• Food production and packaging</td>
<td>• Bullying and harassment of workers</td>
</tr>
<tr>
<td>• Logistics</td>
<td>• Workers in shifts up to 18 hours per day</td>
</tr>
<tr>
<td>• Healthcare</td>
<td>• Prevalence of child labour in cocoa, coffee and palm oil production</td>
</tr>
<tr>
<td>• Medical devices</td>
<td>• Low-cost labour, particularly for items sourced from Asia</td>
</tr>
<tr>
<td>• Surgical instruments</td>
<td>• Pressure to meet unrealistic production targets</td>
</tr>
<tr>
<td>• Electronic medical devices and electronics</td>
<td>• Workers’ exposure to toxic materials</td>
</tr>
<tr>
<td>• IT procurement</td>
<td>• Compromised health and safety standards to produce medical instruments</td>
</tr>
<tr>
<td>• Uniforms</td>
<td>• Forced labour in production of raw materials (particularly metals for electronic components and rubber)</td>
</tr>
<tr>
<td>• Personal Protective Equipment (PPE)</td>
<td>• Forced labour in production of cotton and sweatshop labour in clothing and linen production</td>
</tr>
</tbody>
</table>
HSV risk assessment of Peter Mac contracts 2021-22

As part of its ongoing support to all health services, HealthShare Victoria has worked with Peter Mac to identify potential and actual risks within their portfolio in the past year. The HSV Procurement Policy 1 outlines HSV’s commitment to assist mandated health services by assessing and addressing modern slavery risks in health service supply chains within Collective Purchasing Agreements, with a view to assisting mandated health services with meeting their Reporting Requirement under the Act.

HSV Data and Analytics identified 128 Peter Mac suppliers from the spend data for the period 2021-22. HSV distributed a questionnaire to those 128 suppliers on behalf of Peter Mac. HSV received a response rate of 66% (85 suppliers) refer to Figure 3.

In assessing the 85 suppliers, HSV utilised an assessment tool, comprising of macro and micro assessment components. The outcome of the assessment is detailed in Figure 4 and Figure 5 below. The majority of Peter Mac suppliers (72% or 61 suppliers) register as low to medium risk at the time of reporting, with 28% (24 suppliers) registering in the high to very high risk categories.

<table>
<thead>
<tr>
<th>RISK CATEGORY</th>
<th>NO. OF SUPPLIERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very high</td>
<td>1</td>
</tr>
<tr>
<td>High</td>
<td>23</td>
</tr>
<tr>
<td>Medium</td>
<td>47</td>
</tr>
<tr>
<td>Low</td>
<td>14</td>
</tr>
</tbody>
</table>

In 2021-22, the Foundation has continued to undertake due diligence of its new and existing suppliers to address potential modern slavery risks and undertaken training with its team to increase awareness of modern slavery. The Foundation continues to engage with the Peter Mac Procurement team to ensure its procedures align with expectations in relation to modern slavery.

In 2022-23, the Foundation will:

- Continue to work with Peter Mac Procurement as it further develops its policies and procedures in relation to modern slavery.
- Continue to ensure Foundation subcontractors respond to the modern slavery section of the due diligence questionnaire.
- Perform risk profile screening of suppliers of data services, uniforms, and merchandise, either through the due diligence process or confirming suppliers have provided visibility of their supply chain.
- Consider using other suppliers that have reduced risks in areas of concern.
- Provide training to staff to increase awareness of modern slavery risks in our activities.

The Peter MacCallum Cancer Foundation

The Peter MacCallum Cancer Foundation (the Foundation) is the fundraising arm of Peter Mac. The Foundation raises philanthropic funds to support Peter Mac to accelerate the world’s best cancer research and care in the pursuit of cures for everyone, and all cancers.

Cell Therapies Pty Ltd

Cell Therapies Pty Ltd (CTPL) is an Australian-based, globally active commercial contract development and manufacturing company, specialising in cell therapy, gene therapy, regenerative medicine, and cellular immunotherapy products.

During 2021-2022, CTPL did not identify any specific modern slavery risk areas not already identified by Peter Mac’s Procurement team.
4. THE PAST YEAR – A REVIEW OF OUR MODERN SLAVERY ACTION PLAN

In 2021-22 the Procurement team was continuing to manage the challenges of COVID-19 and the impact to its supply chain.

In the initial year of the COVID-19 pandemic the focus was on supply shortages of PPE and sourcing alternative supply markets. As COVID has continued the challenges have become more focussed on raw material shortages, freight concerns and suppliers exiting challenging markets.

These challenges highlighted the need for Peter Mac to continue to be diligent in the identification of modern slavery risks, particularly as old suppliers exit markets and new ones enter.

Below is the Modern Slavery Framework for the 2021-2022 period.

1. Educate our staff
   Provide modern slavery training to Procurement staff

2. Identify our risks
   Build a risk assessment tool and register for use in contracts and tenders, to identify risks

3. Work with our suppliers and HSV
   Work with our stakeholders and Tier 1 suppliers to identify potential issues in their operations supply chains.
   Work with HSV to identify high risk suppliers.

4. Formalise our framework
   Update our documentation to reflect our ongoing commitment to ending modern slavery practices.
Educating our staff

At an organisational level, the Peter Mac Procurement team have implemented in Peter Mac’s Learning Hub, a customised modern slavery training module from SafeTrac. The procurement team (five staff members) have all completed and passed the training program.

The Director of Procurement and the Procurement Administrator also participate in the HSV Community of Learning program specifically around modern slavery, which has been in place for two reporting periods and is ongoing.

Identify our risks

Peter Mac’s Procurement team developed a Risk Assessment Tool for use by the procurement team in its direct procurement activities to assist in identifying modern slavery risks within the supplier’s supply chain and to provide an overall risk rating.

The risk assessment tool has two components, a mandatory supplier questionnaire and the risk assessment register.

The supplier questionnaire utilises a combined macro and micro-environmental research approach which is based on the risk factors set by the Australian Border Force, refer to Figure 6 below. The questionnaire requires responses relating to provision of documentation such as a supplier’s own Modern Slavery Statement, organisational policies, training, supplier engagement processes and visibility of operations and supply chains in identifying modern slavery risk in their own supply chains.

Responses to the supplier questionnaire along with the overall risk rating are registered on Peter Mac’s Modern Slavery Risk Register which is saved in the Procurement folder on SharePoint. Supplier questionnaires are included with all Peter Mac procurement activity documentation for suppliers to complete and return, this is a mandatory requirement.

**Figure 6.** Macro-environmental risk factors used for Peter Mac risk tool (refer to references for sources used)

<table>
<thead>
<tr>
<th>GEOGRAPHIC RISK</th>
<th>SECTOR &amp; INDUSTRY RISK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reviewed based on location of head office, manufacturing and main operations, service and repair sites and support (Help Desk) locations</td>
<td>Risk is calculated based on the combination of industry sectors and subsectors involved ahead of any procurement activity to be undertaken.</td>
</tr>
<tr>
<td>Checked against countries where there is a real (or potential) risk of modern slavery practice</td>
<td>Ensure that Procurement are aware in advance of any sector conflicts that may require scrutiny during the procurement process to reduce modern slavery risks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SUPPLY CHAIN MODEL RISK</th>
<th>PRODUCT AND SERVICE RISK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reviewed against responses to a questionnaire provided as part of procurement responses;</td>
<td>Calculated based on combination of product sources and country of origins;</td>
</tr>
<tr>
<td>Scores determine actual and potential risk of modern slavery by the supplier, and allows Procurement to put in place at contract commencement additional measures to monitor and remediate supplier as required</td>
<td>Intention of the score is to estimate potential for modern slavery risk within specific product ranges, based on raw materials used, labour practices to manufacture or produce the product of service on offer.</td>
</tr>
</tbody>
</table>
The Risk Assessment Tool has been applied to 13 procurement activities during the 2021-22 reporting period. All 13 suppliers were deemed a medium risk rating. Since this was a new tool for the team, not all suppliers have completed the questionnaire. It is anticipated that the 2022–23 reporting period will see an increase in the number of risk assessments completed.

Refer to Appendix 2 for detail of the 13 suppliers that completed the modern slavery risk assessment questionnaire.

Working with our suppliers and HSV

A natural next step in the modern slavery risk assessment would be to take the information from the risk assessment questionnaire and partner with suppliers that obtained a high-risk rating in order to identify opportunities that would assist in reducing the modern slavery risk within their supply chains. This will form part of the Supplier Contract Management Plan which has yet to be introduced.

Working with HSV

In recognition of the significant role that HSV has in health service supply chains, HSV established a modern slavery program of work and appointed a Supply Chain Risk Manager to implement the program and support Victorian health services to address modern slavery risks in their operations and supply chains. The program encompasses health service education and support, supplier engagement, due diligence and remediation, amongst other activities.

HSV has facilitated training workshops for HSV staff and key health service stakeholders on modern slavery practices and the requirements of the Act. This training is available to Peter Mac Procurement staff in addition to that provided directly by ABR and Safetrac.

Formalising our framework

The intent was to develop a formal procedure that would bring together the Peter Mac modern slavery action plan and provide a transparent process and templates for use by contract managers when engaging suppliers as part of the Supplier Contract Management Program.

Whilst this has not occurred, Peter Mac Procurement have sourced sample clauses from both the Australian Government Department of Finance’s Clause bank, and from HSV for inclusion in Peter Mac standard contracts. The clause has been reviewed and approved by Peter Mac’s General Counsel and is not only incorporated into its standard contracts but is also added into all goods and services contracts regardless of original source.

Peter Mac Procurement have also updated its tender documentation referred to as “The Invitation” to include reference to Peter Mac’s Modern Slavery Statement of Position. As well as updated its mandatory suite of documents for all tenders to include the modern slavery risk questionnaire (previously it was only requested the awarded supplier complete the questionnaire).

Currently, Peter Mac’s Procurement Policy is being updated which will include Peter Mac’s Modern Slavery Statement of Position. This is expected to be reviewed and approved in the next reporting period.
5. THE YEAR AHEAD 2022–2023

With our base framework and several processes implemented, we’re well placed to take the framework to the next level.

The Modern Slavery Framework will be reviewed annually, in order to identify new areas for improvement or opportunities to explore. Whilst the four key points will not change, the supporting actions will. This will also allow the team to adjust focus based on current market trends, as well as Board, HSV and government expectations.

The next financial year will see the focus moving towards utilising the detail obtained in the modern slavery risk questionnaire and partnering with our suppliers to reduce their overall risk. This will commence with the introduction of supplier contract management.

Below is the updated Modern Slavery Framework for the 2022–23 financial year. New areas of focus have been added and highlighted.

1. Educate our staff
   - Provide modern slavery training to Procurement staff
   - Extend modern slavery training to contract managers

2. Identify our risks
   - Build a risk assessment tool and register for use in contracts and tenders, to identify risks
   - Commence supplier contract management with the top spend suppliers.
   - Suppliers on the contract management program have an updated modern slavery risk assessment recorded.

3. Work with our suppliers and HSV
   - Work with our stakeholders and Tier 1 suppliers to identify potential issues in their operations supply chains.
   - Work with HSV to identify high risk suppliers.
   - Suppliers under the contract management program with a high risk rating complete a mitigation plan
   - Review mitigation plan annually with the supplier as part of the supplier contract management program.

4. Formalise our framework
   - Update our documentation to reflect our ongoing commitment to ending modern slavery practices
   - Include reference to modern slavery in our Procurement Policy.
   - Include reference to modern slavery in the Procurement document “The Invitation”.
Educating our staff

With the introduction of Supplier Contract Management in the 2022-23 financial period (refer to Identify our risks below), the procurement team will provide support and training to contract managers to ensure they are prepared to adequately manage suppliers and the associated modern slavery risks, particularly if the supplier has a risk rating of high. This will include extending the online modern slavery training to all contract managers which will provide them with an understanding of the risks associated with modern slavery and the potential impacts on the Peter Mac business. It will also prepare the contract manager to be able to work with suppliers with a high-risk rating and ensure that the supplier has submitted a risk mitigation strategy, and also the subsequent management of that strategy and reporting of it.

Identify our risks

In 2022-23 as part of Identify our risks, Peter Mac will introduce Supplier Contract Management to the top suppliers. Supplier Contract Management creates a formal review process which allows the supplier and the contract manager, as well as key stakeholders the opportunity to review and discuss how the business is operating. This review will also include, particularly for high-risk suppliers, a discussion of their modern slavery risk mitigation plan and what the supplier is doing to reduce their modern slavery supply chain risks.

The reviews will be managed by the contract manager but will be fully supported by Procurement. They are to be minuted with action plans and outcomes documented. The minutes are to be stored in the Contracts register on the Procurement SharePoint.

Currently Peter Mac has 32 contracts with a contracted value over $1m (this is total contract spend not an annual spend. The contract term can be up to five years), Peter Mac’s spend data details 16 suppliers with an annual spend over $1m.

Stage 1 of the roll out of Supplier Contract Management will focus on the top six suppliers with an annual spend over $2m, plus two suppliers which sit just outside of the $2m per annum spend but appear on the top contract spend list.

Stage 2 will see Supplier Contract Management roll out to the balance of the suppliers with an annual spend over $1m (an additional eight suppliers).

Working with our suppliers

In order to commence the Supplier Contract Management program, the nominated suppliers will be requested to complete the modern slavery risk questionnaire. Whilst some suppliers may have completed the questionnaire previously, this will provide the contract manager with a starting base and allow the contract manager to structure the Supplier Contract Management program around the outcome, particularly if the risk rating is high. Any supplier with a risk rating of high is expected to submit a risk mitigation plan which is reviewed annually during the Supplier Contract Management program.

Formalise our framework

As mentioned previously the Procurement Policy is in the process of being updated to remove reference to Melbourne Health and to include reference to several procurement requirements which are mandated by the Government, including modern slavery.

The Policy will be presented to the Board for review and sign off early 2023.

The modern slavery procedure will also be finalised and published prior to the next reporting period.
APPENDIX 1. REFERENCES

1. Annual Report 2022, Peter MacCallum Cancer Centre
2. Modern Slavery Statement Guide for Health Services, HealthShare Victoria, 10/03/2021
5. Resources Used to Develop Peter Mac Risk Assessment Tool 2020-21
   - Global Slavery Index, Walk Free Foundation, 2018
   - Modern Slavery Risks, Rights & Responsibilities, Australian Council of Superannuation Investors, February 2019
   - Do No Harm? Procurement of Medical Goods by Australian Companies and Government, Australian Nursing & Midwifery Federation, 2017
   - Time for a Global Response to Labour Rights Violations in the Manufacture of Health-care goods, Mahmood F Bhutta (World Health Organisation), 2017
   - Modern Slavery Toolkit, HealthShare Victoria, September 2020
6. Modern Slavery Statement Guide for Health Services, HealthShare Victoria, 10/03/2021
# APPENDIX 2. PETER MAC SUPPLIER RISK CATEGORIZATION

<table>
<thead>
<tr>
<th>Supplier</th>
<th>Response</th>
<th>Rating</th>
<th>Modern Slavery Statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spears Constructions</td>
<td>Yes</td>
<td>Medium</td>
<td>TBC</td>
</tr>
<tr>
<td>AlphaXRT Pty Ltd</td>
<td>Yes</td>
<td>Medium</td>
<td>TBC</td>
</tr>
<tr>
<td>Abbott Australasia Pty Ltd</td>
<td>Yes</td>
<td>Medium</td>
<td>TBC</td>
</tr>
<tr>
<td>Diagnostica Stago Pty Ltd</td>
<td>Yes</td>
<td>Medium</td>
<td>TBC</td>
</tr>
<tr>
<td>PerkinElmer Pty Ltd</td>
<td>Yes</td>
<td>Medium</td>
<td>TBC</td>
</tr>
<tr>
<td>Rauland Australia Pty Ltd</td>
<td>Yes</td>
<td>Medium</td>
<td>TBC</td>
</tr>
<tr>
<td>Werfen Australia Pty Ltd</td>
<td>Yes</td>
<td>Medium</td>
<td>TBC</td>
</tr>
<tr>
<td>Decode Science</td>
<td>Yes</td>
<td>Medium</td>
<td>TBC</td>
</tr>
<tr>
<td>Deloitte Australia</td>
<td>Yes</td>
<td>Medium</td>
<td>TBC</td>
</tr>
<tr>
<td>GE Healthcare Pty Ltd</td>
<td>Yes</td>
<td>Medium</td>
<td>TBC</td>
</tr>
<tr>
<td>LabArchives LLC</td>
<td>Yes</td>
<td>Medium</td>
<td>TBC</td>
</tr>
<tr>
<td>Thermo Fisher</td>
<td>Yes</td>
<td>Medium</td>
<td>TBC</td>
</tr>
<tr>
<td>BK Medical Australia Pty Ltd</td>
<td>Yes</td>
<td>Medium</td>
<td>TBC</td>
</tr>
</tbody>
</table>
APPENDIX 3. CONTRACT SPEND OVER $1m

<table>
<thead>
<tr>
<th>CONTRACT MANAGER</th>
<th>SUPPLIER/S</th>
<th>TOTAL COST OF CONTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kosta Gerontzos</td>
<td>VARIAN MEDICAL SYSTEMS AUSTRALASIA PTY LTD</td>
<td>$ 20.8m</td>
</tr>
<tr>
<td>Kosta Gerontzos</td>
<td>ELEKTA PTY LTD</td>
<td>$ 9.3m</td>
</tr>
<tr>
<td>David Aitken</td>
<td>CIRRUS NETWORKS PTY LTD</td>
<td>$ 8m</td>
</tr>
<tr>
<td>Brad Shilling</td>
<td>VARIAN MEDICAL SYSTEMS AUSTRALASIA PTY LTD</td>
<td>$ 5.7m</td>
</tr>
<tr>
<td>Ben O'Sullivan</td>
<td>SIEMENS HEALTHCARE DIAGNOSTICS PTY LTD</td>
<td>$ 5.6m</td>
</tr>
<tr>
<td>David Aitken</td>
<td>DATA GROUP</td>
<td>$ 5.5m</td>
</tr>
<tr>
<td>Teresa Yew</td>
<td>INSIGHT ENTERPRISES AUSTRALIA PTY LTD</td>
<td>$ 4.3m</td>
</tr>
<tr>
<td>David Aitken</td>
<td>PHILIPS HOME HEALTHCARE SOLUTIONS</td>
<td>$ 4.1m</td>
</tr>
<tr>
<td>David Binns</td>
<td>SIEMENS HEALTHCARE DIAGNOSTICS PTY LTD</td>
<td>$ 4m</td>
</tr>
<tr>
<td>Teresa Yew</td>
<td>ADVENT ONE PTY LTD</td>
<td>$ 3.9m</td>
</tr>
<tr>
<td>Ben O'Sullivan</td>
<td>SIEMENS HEALTHCARE DIAGNOSTICS PTY LTD</td>
<td>$ 3.3m</td>
</tr>
<tr>
<td>Tony Mulcahy</td>
<td>GE HEALTHCARE PTY LTD</td>
<td>$ 2.9m</td>
</tr>
<tr>
<td>Anthony Bell</td>
<td>DECODE SCIENCE PTY LTD</td>
<td>$ 2.8m</td>
</tr>
<tr>
<td>Hall Alison</td>
<td>OMNICOMM USA INC</td>
<td>$ 2.8m</td>
</tr>
<tr>
<td>Vuong Nguyen</td>
<td>ABBOTT AUSTRALASIA PTY LTD</td>
<td>$ 2.6m</td>
</tr>
<tr>
<td>Teresa Yew</td>
<td>ADVENT ONE PTY LTD</td>
<td>$ 2.5m</td>
</tr>
<tr>
<td>Ben O'Sullivan</td>
<td>SIEMENS HEALTHCARE DIAGNOSTICS PTY LTD</td>
<td>$ 2.2m</td>
</tr>
<tr>
<td>Teresa Yew</td>
<td>DATA GROUP</td>
<td>$ 2.1m</td>
</tr>
<tr>
<td>Nilgun Touma</td>
<td>ELEKTA PTY LTD</td>
<td>$ 1.9m</td>
</tr>
<tr>
<td>CONTRACT MANAGER</td>
<td>SUPPLIER/S</td>
<td>TOTAL COST OF CONTRACT</td>
</tr>
<tr>
<td>------------------</td>
<td>------------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Lara Sekhon</td>
<td>GLOBAL LIFE SCIENCES SOLUTIONS AUSTRALIA PTY LTD</td>
<td>$1.8m</td>
</tr>
<tr>
<td>Vuong Nguyen</td>
<td>BECTON DICKINSON PTY LTD</td>
<td>$1.8m</td>
</tr>
<tr>
<td>Kosta Gerontzos</td>
<td>ELEKTA PTY LTD</td>
<td>$1.7m</td>
</tr>
<tr>
<td>Anthony Bell</td>
<td>ILLUMINA AUSTRALIA PTY LTD</td>
<td>$1.6m</td>
</tr>
<tr>
<td>Nicole Haynes</td>
<td>ALPHA XRT</td>
<td>$1.5m</td>
</tr>
<tr>
<td>David Aitken</td>
<td>DATA GROUP</td>
<td>$1.5m</td>
</tr>
<tr>
<td>Peter Roselt</td>
<td>GE HEALTHCARE PTY LTD</td>
<td>$1.3m</td>
</tr>
<tr>
<td>Ben OSullivan</td>
<td>SIEMENS HEALTHCARE DIAGNOSTICS PTY LTD</td>
<td>$1.3m</td>
</tr>
<tr>
<td>Cathy Markham</td>
<td>PARAGON CARE GROUP AUSTRALIA PTY LTD</td>
<td>$1.2m</td>
</tr>
<tr>
<td>Anthony Bell</td>
<td>CEPHEID INTERNATIONAL</td>
<td>$1.1m</td>
</tr>
<tr>
<td>Ben OSullivan</td>
<td>SIEMENS HEALTHCARE DIAGNOSTICS PTY LTD</td>
<td>$1.1m</td>
</tr>
<tr>
<td>Lara Sekhon</td>
<td>BIO-STRATEGY DISTRIBUTION PTY</td>
<td>$1m</td>
</tr>
<tr>
<td>Jhoanna VantWout</td>
<td>THE BINDING SITE AUSTRALIA PTY LTD</td>
<td>$1m</td>
</tr>
</tbody>
</table>
## APPENDIX 4. SUPPLIER ANNUAL SPEND OVER $1m

<table>
<thead>
<tr>
<th>SUPPLIER</th>
<th>ANNUAL SPEND</th>
</tr>
</thead>
<tbody>
<tr>
<td>VARIAN MEDICAL SYSTEMS AUSTRALASIA PTY LTD</td>
<td>$ 6.3m</td>
</tr>
<tr>
<td>ELEKTA PTY LTD</td>
<td>$ 3m</td>
</tr>
<tr>
<td>ILLUMINA AUSTRALIA PTY LTD</td>
<td>$ 2.7m</td>
</tr>
<tr>
<td>DATA GROUP</td>
<td>$ 2.6m</td>
</tr>
<tr>
<td>ANSTO RADIOPHARMACEUTICALS</td>
<td>$ 2.2m</td>
</tr>
<tr>
<td>TERUMO BCT AUSTRALIA PTY LIMITED</td>
<td>$ 2.1m</td>
</tr>
<tr>
<td>CIRRUS NETWORKS PTY LTD</td>
<td>$ 1.9m</td>
</tr>
<tr>
<td>THERMO FISHER SCIENTIFIC AUSTRALIA PTY LTD</td>
<td>$ 1.8m</td>
</tr>
<tr>
<td>DEVICE TECHNOLOGIES AUSTRALIA PTY LTD</td>
<td>$ 1.6m</td>
</tr>
<tr>
<td>ICU MEDICAL AUSTRALIA PTY LIMITED</td>
<td>$ 1.5m</td>
</tr>
<tr>
<td>QIAGEN PTY LTD</td>
<td>$ 1.4m</td>
</tr>
<tr>
<td>INTEGRATED SCIENCES</td>
<td>$ 1.3m</td>
</tr>
<tr>
<td>MEDTRONIC AUSTRALASIA PTY LTD</td>
<td>$ 1.2m</td>
</tr>
<tr>
<td>SIEMENS HEALTHCARE PTY LTD</td>
<td>$ 1.1m</td>
</tr>
<tr>
<td>AUSTRALIAN GENOME RESEARCH FACILITY</td>
<td>$ 1.1m</td>
</tr>
<tr>
<td>ROCHE DIAGNOSTICS AUSTRALIA PTY LIMITED</td>
<td>$ 1.1m</td>
</tr>
</tbody>
</table>